Person:
Apel, Petra

Lade...
Profilbild
E-Mail-Adresse
Geburtsdatum
Forschungsvorhaben
Berufsbeschreibung
Nachname
Apel
Vorname
Petra
Name

Suchergebnisse

Gerade angezeigt 1 - 3 von 3
  • Veröffentlichung
    Human Biomonitoring Initiative (HBM4EU): Human Biomonitoring Guidance Values Ddived for dmethylformamide
    (2022) Lamkarkach, Farida; Apel, Petra; Meslin, Matthieu; Kolossa-Gehring, Marike
    Within the European Joint Program on Human Biomonitoring HBM4EU, human biomonitoring guidance values (HBM-GVs) for the general population (HBM-GVGenPop) or for occupationally exposed adults (HBM-GVWorker) are derived for prioritized substances including dimethylformamide (DMF). The methodology to derive these values that was agreed upon within the HBM4EU project was applied. A large database on DMF exposure from studies conducted at workplaces provided dose-response relationships between biomarker concentrations and health effects. The hepatotoxicity of DMF has been identified as having the most sensitive effect, with increased liver enzyme concentrations serving as biomarkers of the effect. Out of the available biomarkers of DMF exposure studied in this paper, the following were selected to derive HBM-GVWorker: total N-methylformamide (tNMF) (sum of N-hydroxymethyl-N-methylformamide and NMF) and N-acetyl-S-(N-methylcarbamoyl)cysteine (AMCC) in urine. The proposed HBM-GVWorker is 10 mgL-1 or 10 mgg-1 creatinine for both biomarkers. Due to their different half-lives, tNMF (representative of the exposure of the day) and AMCC (representative of the preceding days' exposure) are complementary for the biological monitoring of workers exposed to DMF. The levels of confidence for these HBM-GVWorker are set to "high" for tNMF and "medium-low" for AMCC. Therefore, further investigations are required for the consolidation of the health-based HBM-GV for AMCC in urine. © 2022 by the authors
  • Veröffentlichung
    Human biomonitoring initiative (HBM4EU): Human biomonitoring guidance values (HBM-GVs) derived for cadmium and its compounds
    (2021) Lamkarkach, Farida; Apel, Petra; Ougier, Eva; Garnier, Robert; Kolossa-Gehring, Marike; Lange, Rosa
    Aims The methodology agreed within the framework of the HBM4EU project is used in this work to derive HBM-GVs for the general population (HBM-GVGenPop) and for workers (HBM-GVWorker) exposed to cadmium (Cd) and its compounds. Methods For Cd, a significant number of epidemiological studies with doseââą Ìresponse relationships are available, in particular for kidney effects. These effects are described in terms of a relation between urinary Cd (U-Cd) or blood Cd (B-Cd) levels and low molecular weight proteinuria (LMWP) markers like beta-2-microglobulin (Î22M) and retinol-binding protein (RBP). In order to derive HBM-GVs for the general population and workers, an assessment of data from evaluations conducted by national or international organisations was undertaken. In this work, it appeared relevant to select renal effects as the critical effect for the both groups, however, differences between general population (including sensitive people) and workers (considered as an homogenous population of adults who should not be exposed to Cd if they suffer from renal diseases) required the selection of different key studies (i.e. conducted in general population for HBM-GVGenPop and at workplace for HBM-GVWorker). Results and conclusions For U-Cd, a HBM-GVGenPop of 1 (my)g/g creatinine (creat) is recommended for adults older than 50 years, based on a robust meta-analysis performed by EFSA (EFSA, 2009a). To take into account the accumulation of Cd in the human body throughout life, threshold or 'alert' values according to age were estimated for U-Cd. At workplace, a HBM-GVWorker of 2 (my)g/g creat is derived from the study of Chaumont et al., (2011) for U-Cd, and in addition to this recommendation a HBM-GVworker for B-Cd of 5 Ìg/L is also proposed. The HBM-GVWorker for U-Cd is similar to the biological limit value (BLV) set by the new amendment of the European Carcinogens and Mutagens Directive in June 2019 (2 (my)g/g creat for U-Cd). © 2021 The Authors
  • Veröffentlichung
    Europäische Human-Biomonitoring Initiative erfolgreich abgeschlossen
    (2022) Apel, Petra; Kolossa-Gehring, Marike; Lange, Rosa; Pack, Kim Laura; Reiber, Lena; Weise, Philipp
    2017 wurde die Europäische Human Biomonitoring Initiative (HBM4EU) mit dem Ziel gestartet, die Schadstoffbelastung der EU Bevölkerung systematisch zu erfassen. Die Belastungen der europäischen Bevölkerung mit einer Vielzahl von Umweltschadstoffen wurden erstmals vergleichbar ermittelt, bewertet und bereitgestellt. Die Ergebnisse zeigen, dass die Belastungen der EU-Bevölkerung mit vielen Schadstoffen, wie etwa bestimmten Weichmachern und per- und polyfluorierten Alkylsubstanzen (PFAS), zu hoch sind, und gesundheitliche Beeinträchtigungen nicht mit ausreichender Sicherheit ausgeschlossen werden können. Die Erkenntnisse werden an die politischen Entscheidungsträger weitergegeben und sollen bei der Verbesserung der Chemikalien-, Umwelt- und Gesundheitspolitik unterstützen, sodass letztlich gesundheitsrelevante chemische Belastungen minimiert werden. Der folgende Artikel gibt eine Übersicht über die wichtigsten Projektergebnisse. Quelle: UMID : Umwelt und Mensch - Informationsdienst ; Umwelt & Gesundheit, Umweltmedizin, Verbraucherschutz / Boden- und Lufthygiene (Berlin) Institut für Wasser- - (2022), Heft 02, Seite 41